Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2011

View Archived Issues

Novel CRAC inhibitors presented

New antibacterial aminoglycoside derivatives claimed

Merck & Co. patents new gamma-secretase inhibitors

Merrimack regains rights to nanoliposomal irinotecan from PharmaEngine

Favorable preclinical data disclosed on HSP 90 inhibitor MPC-3100

Compound 49b shows promise to treat diabetic retinopathy

Ophthalmic antimicrobial peptide SESB-88V inhibits ocular pathogens

Clinical study finds omalizumab ineffective in treating eosinophilic esophagitis

Intravenous solithromycin is well tolerated in healthy volunteers

Novel tyrosine-protein kinase JAK inhibitors patented by Pfizer

Rib-X Pharmaceuticals discloses new antibacterial agents

New ALK tyrosine kinase receptor inhibitors presented

Institute of Human Virology receives funding for HIV vaccine candidate FLSC

Opsona Therapeutics receives EC grant for clinical development of OPN-305

Chelsea Therapeutics receives approval to open new arm in phase II CH-4051 trial

Astellas and Medivation begin new phase II MDV-3100 trial in prostate cancer

MCD-386CR receives FDA orphan drug status in progressive supranuclear palsy

Wilex completes patient recruitment in phase II Mesupron trial

Alcon Research begins phase II study of AL-59412C

Takeda and Pronova report on pivotal Japanese trial of TAK-085 in hypertriglyceridemia

FDA approves Sanofi Pasteur's new intradermal injection of Fluzone influenza vaccine

Actikerall enters national approval phase in seven European countries for actinic keratosis

EpiCept files protocol for confirmatory phase III Ceplene trial in AML

Bayer's regorafenib receives FDA fast track status in GIST

CCL21-vaults have antitumor effects in model of lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...